Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 16, 2024

SELL
$12.64 - $30.11 $55,603 - $132,453
-4,399 Reduced 30.41%
10,066 $226,000
Q3 2023

Oct 24, 2023

BUY
$16.64 - $25.32 $68,357 - $104,014
4,108 Added 39.66%
14,465 $240,000
Q2 2023

Jul 25, 2023

SELL
$21.59 - $27.88 $19,193 - $24,785
-889 Reduced 7.91%
10,357 $253,000
Q1 2023

Apr 14, 2023

BUY
$23.46 - $36.44 $48,327 - $75,066
2,060 Added 22.43%
11,246 $271,000
Q4 2022

Feb 08, 2023

BUY
$27.82 - $44.16 $25,510 - $40,494
917 Added 11.09%
9,186 $271,000
Q3 2022

Oct 25, 2022

SELL
$16.33 - $51.06 $16,509 - $51,621
-1,011 Reduced 10.89%
8,269 $346,000
Q2 2022

Aug 12, 2022

SELL
$17.22 - $38.47 $45,891 - $102,522
-2,665 Reduced 22.31%
9,280 $261,000
Q1 2022

May 11, 2022

BUY
$32.6 - $53.05 $119,968 - $195,224
3,680 Added 44.53%
11,945 $444,000
Q4 2021

Feb 08, 2022

BUY
$36.77 - $90.91 $93,175 - $230,365
2,534 Added 44.22%
8,265 $361,000
Q3 2021

Nov 02, 2021

BUY
$41.79 - $135.3 $77,520 - $250,981
1,855 Added 47.86%
5,731 $356,000
Q2 2021

Aug 11, 2021

BUY
$32.15 - $89.72 $124,613 - $347,754
3,876 New
3,876 $331,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $109M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.